Asset Details
Do you wish to reserve the book?
Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients
Do you wish to request the book?
Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients
2020
Overview
Chronic hepatitis B (CHB) infection functional cure is defined as sustained loss of HBsAg and several therapeutic strategies are in clinical development designed to pharmacologically reduce serum HBsAg, break immune tolerance, and increase functional cure rates. However, little is known about pre-treatment HBsAg levels as an indicator of HBV immune potential. Here, we compared the phenotypes and HBV-specific response of lymphocytes in CHB patients stratified by serum HBsAg levels <500 (HBs
lo
) or >50,000 IU/ml (HBs
hi
) using immunological assays (flow cytometry, ICS, ELISPOT). HBs
hi
patients had significantly higher expression of inhibitory PD-1 on CD4
+
T cells, particularly among TEMRA subset, and higher FcRL5 expression on B cells. Upon HBcAg(core) or HBsAg(env)-stimulation, 85% and 60% of HBs
lo
patients had IFNγ
+
TNFα
+
and IFNγ
+
IL2
+
CD4
+
T cell responses respectively, in comparison to 33% and 13% of HBs
hi
patients. Checkpoint blockade with αPD-1 improved HBV-specific CD4
+
T cell function only in HBs
lo
patients. HBsAg-specific antibody-secreting cells (ASCs) response was not different between these groups, yet αPD-1 treatment resulted in significantly higher fold change in ASCs among patients with HBsAg <100 IU/ml compared to patients with HBsAg >5,000 IU/ml. Thus, serum HBsAg correlates with inhibitory receptor expression, HBV-specific CD4
+
T cell responses, and augmentation by checkpoint blockade.
Publisher
Nature Publishing Group UK,Nature Publishing Group
